Novavax (NVAX) has been under a strong bear grip, hence the stock is down -2.17% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 3.93% in the past 1 week. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 4.37% in the last 1 week, and is up 0.26% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
Novavax (NASDAQ:NVAX): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $7.55 and $7.51 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $7.70. The buying momentum continued till the end and the stock did not give up its gains. It closed at $7.64, notching a gain of 1.73% for the day. The total traded volume was 2,731,510 . The stock had closed at $7.51 on the previous day.
The stock has recorded a 20-day Moving Average of 2.43% and the 50-Day Moving Average is 9.75%. Novavax, Inc. is up 65.73% in the last 3-month period. Year-to-Date the stock performance stands at -8.94%.
Novavax (NVAX) : 6 Wall Street analysts covering Novavax (NVAX) believe that the average level the stock could reach for the short term is $13.15. The maximum price target given is $17 and the minimum target for short term is around $6, hence the standard deviation is calculated at $3.81.
Novavax, Inc. (Novavax) is a clinical-stage vaccine company engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. The Companys product pipeline focuses on a variety of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Companys lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. The Company is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. The Company is developing additional pre-clinical stage programs in a variety of infectious diseases, including Middle East respiratory syndrome (MERS).